Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N0V5

UPID:
GNT2A_HUMAN

ALTERNATIVE NAMES:
I-branching enzyme; IGNT

ALTERNATIVE UPACC:
Q8N0V5; Q06430; Q5T4J1; Q5W0E9; Q6T5E5; Q8NFS9

BACKGROUND:
The enzyme N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase, known alternatively as I-branching enzyme or IGNT, is crucial for the biosynthesis of branched poly-N-acetyllactosaminoglycans and the expression of the blood group I antigen in erythrocytes. Its activity is essential for proper erythroid cell development and maturation.

THERAPEUTIC SIGNIFICANCE:
Variants affecting this enzyme cause Cataract 13, with adult i phenotype, highlighting its significance in ocular health. The exploration of N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase's function offers promising avenues for developing treatments for related visual impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.